Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSAT:DBP B's PB Ratio is ranked better than 62.62% of 1228
companies
in the Biotechnology industry
Industry Median: 2.705
vs XSAT:DBP B: 1.91
During the past 12 months, Double Bond Pharmaceutical International AB's average Book Value Per Share Growth Rate was 151.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -36.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.30% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Double Bond Pharmaceutical International AB was 193.90% per year. The lowest was -54.80% per year. And the median was -31.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Double Bond Pharmaceutical International AB PB Ratio Related Terms
Double Bond Pharmaceutical International AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB PB Ratio Chart
Double Bond Pharmaceutical International AB Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Double Bond Pharmaceutical International AB PB Ratio vs Biotechnology Industry
Double Bond Pharmaceutical International AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a PB Ratio of 1.92 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Double Bond Pharmaceutical International AB and its competitors. This is 63% below median its historical median of 5.13. Over the past decade, Double Bond Pharmaceutical International AB's PB Ratio has ranged from 0.89 to 149.43. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #459 out of 1228 companies in the Biotechnology industry, placing it in the top 37.4%.
Is Double Bond Pharmaceutical International AB's PB Ratio too high?
Double Bond Pharmaceutical International AB's current PB Ratio of 1.92 is 63% below median its 10-year median of 5.13. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 149.43. The Biotechnology industry median PB Ratio is 2.71. Double Bond Pharmaceutical International AB's value of 1.92 is 29% below this industry median. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #459 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #459 out of 1228 companies for PB Ratio. This puts Double Bond Pharmaceutical International AB in the upper half of its industry. The industry median PB Ratio is 2.71. Double Bond Pharmaceutical International AB's value of 1.92 is 29% below this benchmark. Historically, Double Bond Pharmaceutical International AB's own PB Ratio has ranged from 0.89 to 149.43 over the past decade. While the company's 10-year median is 5.13 vs. the industry median of 2.71, Double Bond Pharmaceutical International AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.71, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Double Bond Pharmaceutical International AB's current PB Ratio of 1.92 is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Double Bond Pharmaceutical International AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Double Bond Pharmaceutical International AB's current PB Ratio is 1.92, which is 63% below median its own 10-year median of 5.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.13 — trading 117.5% above its estimated fair value. The current PB Ratio is 1.92, which is 63% below median its 10-year median of 5.13 and 29% below the Biotechnology industry median of 2.71. Double Bond Pharmaceutical International AB's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current PB Ratio is 1.92 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued.
The current stock price of kr0.13 is trading 117.5% above its estimated GF Value™ of kr0.06.
GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.
Key valuation signals for XSAT:DBP B:
PB Ratio: 1.92 (63% below median its 10-year median of 5.13)
GF Value™: kr0.06 vs. price of kr0.13 (117.5% above fair value)
Industry Position: 29% below the Biotechnology median (#459 of 1228)
No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
29GF Score
Get the complete analysis for XSAT:DBP B
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DBP B has been successfully added to your 
